Purple Biotech Q3 EPS $(0.60) Beats $(2.88) Estimate
Benzinga Newsdesk 4 days ago
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Purple Biotech (NASDAQ:PPBT) reported quarterly losses of $(0.60) per share which beat the analyst consensus estimate of $(2.88) by 79.17 percent. This is a 79.02 percent increase over losses of $(2.86) per share from
Purple Biotech (NASDAQ:PPBT) reported quarterly losses of $(0.60) per share which beat the analyst consensus estimate of $(2.88) by 79.17 percent. This is a 79.02 percent increase over losses of $(2.86) per share from the same period last year.
More on PPBT
Benzinga
Purple Biotech Presents Preclinical Data On IM1240, Lead Capped Tri-Specific Antibody From CAPTN-3 Platform, In Plenary Oral Session At 38th EORTC-NCI-AACR SymposiumPlenary oral presentation by Mount Sinai immunologist Dr. Amir Horowitz highlights Purple Biotech's CAPTN-3 platform of capped tri-specific antibodies, designed to engage T cells and NK cells against…
